drugset / Trial / NCT04425291
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3
Completed
1680 enrolled
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
Timeline
- Start
- 2020-05-28
- Primary completion
- 2021-09-06
- Completion
- 2021-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 4-valent HPV Vaccine | Vaccine | — | — |
| Subject | 9-valent HPV vaccine | Vaccine | — | — |
| Comparator | Gardasil | Vaccine | — | — |